What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source
GLP-1 receptor agonists for Parkinson's disease
Cochrane Database of Systematic Reviews, 2020 Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.
Caroline A, Mulvaney +6 more
openaire +3 more sources
Pharmaceuticals, 2022 Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type
Ali Ismaeil +2 more
doaj +1 more source
Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]
, 2014 Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D. +3 more
core +2 more sources
Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD) [PDF]
Avicenna Journal of Medical Biochemistry, 2017 Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-1 (GLP-1) is a significant regulator of
Ebrahim Abbasi Oshaghi
doaj +1 more source
Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway [PDF]
, 2015 The glucagon like peptide-1 receptor (GLP-1R) is a G-protein coupled receptor (GPCR) and an important target in the treatment of type 2 diabetes mellitus (T2DM).
Aiysha Thompson +71 more
core +1 more source
Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. [PDF]
PLoS ONE, 2017 Glucagon-like peptide-1 (GLP-1) receptor plays an essential role in regulating glucose metabolism. GLP-1 receptor agonists have been widely used for treating diabetes and other insulin resistance-related diseases.
Anping Wang +6 more
doaj +1 more source
Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi +64 more
core +6 more sources
Adverse Effects of GLP-1 Receptor Agonists [PDF]
The Review of Diabetic Studies, 2014 Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain adverse effects.
Theodosios D, Filippatos +2 more
openaire +2 more sources
GLP-1 receptor agonists and the risk of thyroid cancer
Diabetes Care, 2022 <p> </p> <p><em>Objective</em></p> <p>To determine whether the use of GLP-1 receptor agonists (RA) is associated with an increased risk of thyroid cancer.</p> <p><em>Research Design and Methods</em></p> <p>A nested case-control analysis was performed using the French ...
Bezin, Julien +7 more
openaire +3 more sources